What is it? Why is it important?

Patient and Public Involvement (PPI) refers to research carried out with or by patients and members of the public rather than to, about, or for them.

Beyond scientific and research community interests, study feasibility may highly depend on issues targeting the population under investigation. Especially during the concept phase, PPI can provide valuable information to participant-related risks and challenges affecting study planning and set-up.

 

Patients provide insights that are not always visible to researchers, but may have a significant effect on the successful implementation of the study. Thus, integrating patient perspectives through PPI may help identify and mitigate potential risks threatening study feasibility.

What do I need to do?

As a SP-INV, assess the study from a patient perspective.

 

Patient-related feasibility questions may include:

  • Is the study design, including the expected participant burden, manageable for the target patient population?
  • Are expected patient tasks feasible and acceptable to ensure successful patient compliance and, avoiding early patient drop-out (e.g. medication intake, provision of biological material, daily diaries, study-required activities, use of technology)?
  • Despite risks and burdens, will the patient population perceive the study as participant-friendly?

 

As a SP-INV, recruit patient partners and ask them to:

  • Identify potential barriers to study participation (e.g. inclusion and exclusion criteria)
  • Identify constraints to study compliance (e.g. study-required tasks, visit frequency, travel)
  • Assess whether the study outcomes are meaningful and relevant to patients, and whether the results could improve health and quality of life

 

Include feasibility assessments from a site perspective, as local conditions may affect participant burden, compliance and study participation.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissethics - see in particular

References

Abbreviations
  • PPI – Patient and Public Involvement
  • SP-INV – Sponsor Investigator
Concept ↦ Quality and Risk ↦ Study Feasibility ↦ Patient and Public Involvement
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Concept ↦ Quality and Risk ↦ Study Feasibility ↦ Patient and Public Involvement